MX2011012913A - Métodos para evaluar el riesgo de cáncer de mama. - Google Patents

Métodos para evaluar el riesgo de cáncer de mama.

Info

Publication number
MX2011012913A
MX2011012913A MX2011012913A MX2011012913A MX2011012913A MX 2011012913 A MX2011012913 A MX 2011012913A MX 2011012913 A MX2011012913 A MX 2011012913A MX 2011012913 A MX2011012913 A MX 2011012913A MX 2011012913 A MX2011012913 A MX 2011012913A
Authority
MX
Mexico
Prior art keywords
risk assessment
methods
breast cancer
cancer risk
relates
Prior art date
Application number
MX2011012913A
Other languages
English (en)
Inventor
David A Hinds
Bryan Walser
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of MX2011012913A publication Critical patent/MX2011012913A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

La presente invención se relaciona con métodos y sistemas para evaluar el riesgo general de una mujer para desarrollar un fenotipo de cáncer de mama. En particular, la presente invención se relaciona con combinar la evaluación del riesgo clínico y la evaluación del riesgo genético para mejorar el análisis del riesgo.
MX2011012913A 2009-06-01 2010-06-01 Métodos para evaluar el riesgo de cáncer de mama. MX2011012913A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18280909P 2009-06-01 2009-06-01
US25842009P 2009-11-05 2009-11-05
PCT/AU2010/000675 WO2010139006A1 (en) 2009-06-01 2010-06-01 Methods for breast cancer risk assessment

Publications (1)

Publication Number Publication Date
MX2011012913A true MX2011012913A (es) 2012-02-21

Family

ID=43297192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012913A MX2011012913A (es) 2009-06-01 2010-06-01 Métodos para evaluar el riesgo de cáncer de mama.

Country Status (13)

Country Link
US (2) US20110294681A1 (es)
EP (1) EP2438193B1 (es)
JP (1) JP5976533B2 (es)
CN (1) CN102712949B (es)
AU (1) AU2010256343B2 (es)
BR (1) BRPI1011979A2 (es)
CA (1) CA2763500C (es)
DK (1) DK2438193T3 (es)
ES (1) ES2546230T3 (es)
HK (1) HK1168387A1 (es)
IL (1) IL216627A (es)
MX (1) MX2011012913A (es)
WO (1) WO2010139006A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087854A1 (en) * 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
AU2006320559B2 (en) 2005-11-29 2012-01-19 Cambridge Enterprise Limited Markers for breast cancer
US8463554B2 (en) 2008-12-31 2013-06-11 23Andme, Inc. Finding relatives in a database
AU2010256343B2 (en) 2009-06-01 2014-01-30 Genetic Technologies Limited Methods for breast cancer risk assessment
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US10437858B2 (en) 2011-11-23 2019-10-08 23Andme, Inc. Database and data processing system for use with a network-based personal genetics services platform
CA2886814C (en) * 2012-10-02 2021-09-07 Sphingotec Gmbh A method for predicting the risk of getting cancer or diagnosing cancer in a female subject
CN103966310A (zh) * 2014-01-27 2014-08-06 广州市体育科学研究所 乳腺癌易感基因快速检测试剂盒及检测方法
JP6820838B2 (ja) * 2014-09-30 2021-01-27 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクを評価する方法
WO2016061246A1 (en) * 2014-10-14 2016-04-21 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with cancer risk
JP7043404B2 (ja) * 2015-12-07 2022-03-29 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
JP2020508643A (ja) * 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクの改良された評価法
JP6935079B2 (ja) * 2017-05-09 2021-09-15 国立大学法人千葉大学 機能的ｓｎｐの組合せ解析
US11861491B2 (en) * 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
NZ759818A (en) 2017-10-16 2022-04-29 Illumina Inc Semi-supervised learning for training an ensemble of deep convolutional neural networks
US11081217B2 (en) * 2017-12-21 2021-08-03 Basehealth, Inc. Systems and methods for optimal health assessment and optimal preventive program development in population health management
AU2019370896A1 (en) 2018-10-31 2021-06-17 Ancestry.Com Dna, Llc Estimation of phenotypes using DNA, pedigree, and historical data
CN109971856A (zh) * 2019-04-15 2019-07-05 无锡芯超生物科技有限公司 用于评估人类受检者罹患肺癌的试剂盒或系统及应用
EP4031688B1 (en) 2019-10-22 2023-07-12 Sistemas Genómicos, S.L. In vitro method for determining the risk of developing breast cancer in a subject
CN113299400B (zh) * 2021-06-23 2023-02-21 复旦大学附属儿科医院 新生儿危重症遗传风险评估方法、装置及设备

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4240602A (en) 1979-03-19 1980-12-23 The Babcock & Wilcox Company Support device for a pressure vessel
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
AU723400B2 (en) 1996-11-07 2000-08-24 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
WO2000033161A2 (en) 1998-12-02 2000-06-08 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) * 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
US20050084849A1 (en) 2000-07-25 2005-04-21 Moskowitz David W. Diagnostic polymorphisms for the ecnos promoter
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) * 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
AU2004271164A1 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
AU2006320559B2 (en) 2005-11-29 2012-01-19 Cambridge Enterprise Limited Markers for breast cancer
US20080009419A1 (en) * 2006-06-23 2008-01-10 Intergenetics, Inc. Genetic models for stratification of cancer risk
AU2007325021B2 (en) * 2006-11-30 2013-05-09 Navigenics, Inc. Genetic analysis systems and methods
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20110117545A1 (en) * 2007-03-26 2011-05-19 Decode Genetics Ehf Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2535425A1 (en) * 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
EP2176426A2 (en) * 2007-07-11 2010-04-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
WO2010017520A1 (en) * 2008-08-08 2010-02-11 Navigenics, Inc. Methods and systems for personalized action plans
KR20110074527A (ko) * 2008-09-12 2011-06-30 네이비제닉스 인크. 복수의 환경 및 유전 위험 인자를 통합하기 위한 방법 및 시스템
AU2010256343B2 (en) 2009-06-01 2014-01-30 Genetic Technologies Limited Methods for breast cancer risk assessment
WO2013151413A1 (en) 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
JP6820838B2 (ja) 2014-09-30 2021-01-27 ジェネティック テクノロジーズ リミテッド 乳癌発症リスクを評価する方法

Also Published As

Publication number Publication date
IL216627A (en) 2016-08-31
CN102712949A (zh) 2012-10-03
CN102712949B (zh) 2015-12-16
EP2438193A4 (en) 2012-11-21
US20110294681A1 (en) 2011-12-01
AU2010256343B2 (en) 2014-01-30
JP2012528573A (ja) 2012-11-15
AU2010256343A1 (en) 2011-12-22
EP2438193B1 (en) 2015-07-22
WO2010139006A1 (en) 2010-12-09
CA2763500A1 (en) 2010-12-09
BRPI1011979A2 (pt) 2020-10-06
EP2438193A1 (en) 2012-04-11
ES2546230T3 (es) 2015-09-21
JP5976533B2 (ja) 2016-08-23
IL216627A0 (en) 2012-02-29
DK2438193T3 (en) 2015-10-19
US20180080089A1 (en) 2018-03-22
US11072830B2 (en) 2021-07-27
CA2763500C (en) 2019-09-03
HK1168387A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
MX2011012913A (es) Métodos para evaluar el riesgo de cáncer de mama.
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
MX361944B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
UA114277C2 (uk) Антиангіогенна терапія для лікування раку яєчника
EP2663656A4 (en) GENETIC VARIANTS AS A MARKER FOR USE IN THE DETERMINATION, DIAGNOSIS, FORECAST AND TREATMENT OF A HARLBASIS CANCER RISK
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
GB2535914B (en) Biomarkers useful for detection of types, grades and stages of human breast cancer
MX2013015409A (es) Diagnostico de la enfermedad de alzheimer.
MX358726B (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
EP2473854A4 (en) SYSTEMS AND METHODS FOR TREATMENT, DIAGNOSIS AND PREDICTION OF RESPONSE TO BREAST CANCER THERAPY
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.
SG194235A1 (en) Methods of predicting the development of complement-mediated disease
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.

Legal Events

Date Code Title Description
FG Grant or registration